[{"id":"a6cb88f4-ba00-49e4-9c5c-73bf0aba5d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03651271","created_at":"2021-02-22T18:20:29.505Z","updated_at":"2025-02-25T14:27:31.902Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer","source_id_and_acronym":"NCT03651271","lead_sponsor":"Parker Institute for Cancer Immunotherapy","biomarkers":" CD8","pipe":" | ","alterations":" CD8-H","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 10/17/2018","start_date":" 10/17/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2024-02-07"},{"id":"7a5ec2b9-2dde-4391-a7e7-389414d037b9","acronym":"PRIMUNEO","url":"https://clinicaltrials.gov/study/NCT01513408","created_at":"2021-01-18T06:21:40.277Z","updated_at":"2024-07-02T16:35:33.050Z","phase":"","brief_title":"Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy","source_id_and_acronym":"NCT01513408 - PRIMUNEO","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" HER-2 • CD8 • FOXP3","pipe":" | ","alterations":" HR positive • CD8-H","tags":["HER-2 • CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • CD8-H"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-10-17"}]